Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mou… Read more
Staidson Beijing Biopharma (300204) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.046x
Based on the latest financial reports, Staidson Beijing Biopharma (300204) has a cash flow conversion efficiency ratio of -0.046x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-39.18 Million) by net assets (CN¥859.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Staidson Beijing Biopharma - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Staidson Beijing Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Staidson Beijing Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Staidson Beijing Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mercialys
PINK:MEIYF
|
0.127x |
|
CRISIL Limited
NSE:CRISIL
|
0.073x |
|
Chongqing Three Gorges Water Conservancy and Electric Power Co Ltd
SHG:600116
|
0.048x |
|
InterRent Real Estate Investment Trust
PINK:IIPZF
|
0.009x |
|
Huapont Life Sciences Co Ltd
SHE:002004
|
0.039x |
|
MY EG Services Bhd
KLSE:0138
|
0.057x |
|
Ninety One Group
PINK:NINTF
|
-0.228x |
|
Guodian Nanjing Automation Co Ltd
SHG:600268
|
-0.064x |
Annual Cash Flow Conversion Efficiency for Staidson Beijing Biopharma (2007–2024)
The table below shows the annual cash flow conversion efficiency of Staidson Beijing Biopharma from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥916.76 Million | CN¥-63.68 Million | -0.069x | +68.83% |
| 2023-12-31 | CN¥1.02 Billion | CN¥-227.47 Million | -0.223x | -71.83% |
| 2022-12-31 | CN¥1.35 Billion | CN¥-175.60 Million | -0.130x | -24.10% |
| 2021-12-31 | CN¥1.55 Billion | CN¥-162.07 Million | -0.105x | -44.78% |
| 2020-12-31 | CN¥1.59 Billion | CN¥-114.60 Million | -0.072x | -366.21% |
| 2019-12-31 | CN¥1.64 Billion | CN¥44.34 Million | 0.027x | -59.63% |
| 2018-12-31 | CN¥2.46 Billion | CN¥165.08 Million | 0.067x | -45.77% |
| 2017-12-31 | CN¥2.21 Billion | CN¥273.64 Million | 0.124x | +11.78% |
| 2016-12-31 | CN¥1.92 Billion | CN¥212.55 Million | 0.111x | -19.24% |
| 2015-12-31 | CN¥1.68 Billion | CN¥231.01 Million | 0.137x | +0.44% |
| 2014-12-31 | CN¥1.51 Billion | CN¥206.85 Million | 0.137x | +61.17% |
| 2013-12-31 | CN¥1.31 Billion | CN¥111.36 Million | 0.085x | +16.61% |
| 2012-12-31 | CN¥1.24 Billion | CN¥90.19 Million | 0.073x | -7.94% |
| 2011-12-31 | CN¥1.10 Billion | CN¥87.01 Million | 0.079x | -79.46% |
| 2010-12-31 | CN¥166.23 Million | CN¥63.91 Million | 0.384x | +8.64% |
| 2009-12-31 | CN¥119.72 Million | CN¥42.37 Million | 0.354x | +36.99% |
| 2008-12-31 | CN¥62.82 Million | CN¥16.23 Million | 0.258x | +61.81% |
| 2007-12-31 | CN¥33.87 Million | CN¥5.41 Million | 0.160x | -- |